Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFLUENCE: Intra-operative fluorescent c-MET tracer imaging in penile, oral cavity, and renal cancer
2024-518046-25-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emi-137 in renal cell carcinoma (RCC), penile cancer and lingual carcinoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Feasibility of intra-operative tumor visualization. Planned start Dec 2019; status: authorised.
02
Drugs
emi-137
03
Conditions
renal cell carcinoma (RCC)penile cancerlingual carcinoma
Beyond the preview
Go deeper on 2024-518046-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518046-25-00.